A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis Read more
Assessing Survival Outcomes of Blinatumomab Therapy Following Donor Lymphocyte Infusion and Allogeneic Stem Cell Transplant in Acute Lymphoblastic Leukemia and CML in Lymphoid Blast Crisis Patients Read more
An Open-label, Phase 1b Study of study drug in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies Read more
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD) Read more
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status Read more
